Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249485 | 1.00 | CHRNB2 (0.35) | CHRNB2CHRNA4KDM1AKCNH2TDP1 | |
| SCHEMBL20249232 | 0.90 | CLK2 (0.37) | CHRNB2CHRNA4KCNH2CSF1RFLT3 | |
| SCHEMBL20249381 | 0.90 | CLK2 (0.37) | CHRNB2CHRNA4KCNH2CSF1RFLT3 | |
| SCHEMBL20249229 | 0.90 | CLK2 (0.37) | CHRNB2CHRNA4KCNH2CSF1RFLT3 | |
| SCHEMBL20249367 | 0.88 | CHRNB2 (0.32) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL20038365 | 0.83 | CHRNB2 (0.40) | CHRNB2CHRNA4KDM1ATDP1 | |
| SCHEMBL18291676 | 0.83 | CHRNB2 (0.40) | CHRNB2CHRNA4KDM1ATDP1 | |
| SCHEMBL20249288 | 0.81 | CHRNB2 (0.54) | CHRNB2CHRNA4PRKCZ | |
| SCHEMBL20249289 | 0.81 | CHRNB2 (0.54) | CHRNB2CHRNA4PRKCZ | |
| SCHEMBL20249208 | 0.81 | CHRNB2 (0.54) | CHRNB2CHRNA4PRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CHRNB2 4863/4885CHRNA4 4628/4885KDM1A 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.